Author

Y. Kuwahara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Kentsis· 2 shared A. L. Kung· 2 shared E. De Stanchina· 2 shared F. S. Dela Cruz· 2 shared H. Hosoi· 2 shared A. Califano· 1 shared A. Henssen· 1 shared A. Kung· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Kentsis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

bioRxiv · Feb 6, 2023Cancer Biology

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors - expanding patient-driven discovery beyond the Nof1.

L. J. Marks, D. Diolaiti, P. Mundi, E. S. Gaviria, A. R. Rainey, D. J. Yamashiro, L. Fazlollahi, H. Hosoi, Y. Katsumi, Y. Kuwahara, F. S. Dela Cruz, A. Califano, A. L. Kung

This study identifies XPO1 activation as a non-genetic vulnerability in malignant rhabdoid tumors using patient-driven discovery and validates selinexor as a potential therapeutic.

bioRxiv · Oct 2, 2021 · PreprintCancer Biology

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

A. Henssen, C. Reed, E. Jiang, H. D. Garcia, J. von Stebut, I. MacArthur, P. Hundsdoerfer, J. Hyun Kim, E. de Stanchina, Y. Kuwahara, H. Hosoi, N. Ganem, F. Dela Cruz, A. Kung, J. Schulte, , A. Kentsis

This study identifies PGBD5 as a therapeutic target in pediatric solid tumors, showing that inhibiting DNA repair pathways with AZD6738 sensitizes these tumors to apoptosis.

bioRxiv · Aug 25, 2017Cancer Biology